RIDGEFIELD, CT – The US Food and Drug Administration (FDA) has approved dabigatran (Pradaxa, Boehringer Ingelheim) for treating deep vein thrombosis (DVT) and pulmonary
embolism (PE) in
patients who have been treated with a parenteral anticoagulant for five to 10 days.
The FDA also approved dabigatran to reduce the risk of DVT/PE recurrence in patients who have been previously treated. The approval is based on four studies testing dabigatran in the setting of venous thromboembolism (VTE).
See more at: http://www.medscape.com/viewarticle/823159